BofA

Tazeen Ahmad

Q: How accurate are Tazeen Ahmad's stock ratings?

About 48% of Tazeen's ratings were profitable over a one-year hold, with an average return of -2.0% per rating, measured by 13Foresight from historical prices.

Q: How is Tazeen ranked?

Tazeen Ahmad is ranked #2313 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Bank of America Securities

Wall Street Analyst

★★☆☆☆

#2313

on 13Foresight · ranked by our own returns

49%

Success Rate

-2.0%

Average Return

73 of 149 calls profitable · +17.0% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 49% of Tazeen Ahmad's ratings turned a profit when each position was held for 1 year — averaging -2.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

281 Buy 31 Hold 40 Sell

Tazeen's Stock Coverage 60 ratings · 2026-09-23

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
ARGX Argenx Se	Sep 21, 2026	BUY	Strong Buy -14.0% avg upside 48 analysts	$1136.00 17.91% Upside	·	·
RARE Ultragenyx Pharmaceutical	Sep 18, 2026	HOLD	Strong Buy +221.7% avg upside 36 analysts	$20.00 28.15% Upside	+0.0%	·
PBLS Parabilis Medicines, Inc.	Sep 16, 2026	BUY	Strong Buy +18.4% avg upside 6 analysts	$45.00 17.93% Upside	+13.2%	·
SRRK Scholar Rock Holding	Sep 16, 2026	BUY	Strong Buy +27.9% avg upside 23 analysts	$72.00 40.69% Upside	+1.0%	·
OCUL Ocular Therapeutix	Sep 15, 2026	BUY	Strong Buy +135.2% avg upside 21 analysts	$27.00 157.11% Upside	-2.0%	·
ASND Ascendis Pharma	Sep 15, 2026	BUY	Strong Buy +20.3% avg upside 26 analysts	$304.00 27.87% Upside	-1.3%	·
BNTX BioNTech SE	Sep 14, 2026	BUY	Strong Buy +33.2% avg upside 26 analysts	$122.00 20.94% Upside	-2.8%	·
KYMR Kymera Therapeutics	Sep 14, 2026	BUY	Strong Buy -9.0% avg upside 37 analysts	$144.00 17.99% Upside	+2.6%	·
DFTX Definium Therapeutics	Sep 14, 2026	BUY	Strong Buy +31.8% avg upside 23 analysts	$91.00 125.69% Upside	-2.4%	·
PHVS Pharvaris	Sep 08, 2026	HOLD	Strong Buy +59.5% avg upside 15 analysts	$44.00 25.00% Upside	-4.8%	·
AMGN Amgen	Sep 08, 2026	SELL	Buy -21.7% avg upside 57 analysts	$317.00 22.81% Downside	-4.8%	·
BLTE Belite Bio, Inc. ADR	Sep 02, 2026	BUY	Strong Buy +15.5% avg upside 11 analysts	$200.00 14.05% Upside	+6.4%	·
ALNY Alnylam Pharma	Aug 31, 2026	BUY	Strong Buy +26.6% avg upside 51 analysts	$346.00 37.49% Upside	+1.5%	·
STRO Sutro Biopharma	Aug 14, 2026	SELL	Strong Buy +155.5% avg upside 21 analysts	—	+20.2%	·
AARD Aardvark Therapeutics, Inc.	Aug 14, 2026	SELL	Buy +239.3% avg upside 12 analysts	—	+15.0%	·
ANRO Alto Neuroscience, Inc.	Aug 14, 2026	BUY	Strong Buy +4.0% avg upside 13 analysts	—	-4.7%	·
IMMX Immix Biopharma	Aug 14, 2026	BUY	Strong Buy +56.5% avg upside 9 analysts	—	+14.0%	·
TSHA Taysha Gene Therapies	Aug 14, 2026	BUY	Strong Buy +174.1% avg upside 22 analysts	—	-14.9%	·
PRTA Prothena	Aug 14, 2026	SELL	Buy +178.5% avg upside 14 analysts	—	+3.8%	·
PTCT PTC Therapeutics	Aug 13, 2026	BUY	Buy +23.4% avg upside 29 analysts	$96.00 45.63% Upside	-9.2%	·
ANNX Annexon Biosciences	Aug 12, 2026	BUY	Strong Buy +237.5% avg upside 14 analysts	$8.00 91.43% Upside	-20.6%	·
BCAX Bicara Therapeutics Inc.	Aug 11, 2026	BUY	Strong Buy +45.5% avg upside 16 analysts	$34.00 49.18% Upside	-4.7%	·
VRTX Vertex Pharmaceuticals	Aug 10, 2026	BUY	Strong Buy -13.7% avg upside 62 analysts	$672.00 30.53% Upside	-3.0%	·
DNLI Denali Therapeutics	Aug 07, 2026	BUY	Strong Buy +80.4% avg upside 24 analysts	$31.00 43.49% Upside	-17.6%	·
PEPG PepGen Inc.	Aug 07, 2026	SELL	Strong Buy +258.5% avg upside 9 analysts	$2.50 16.17% Downside	-0.0%	·
FULC Fulcrum Therapeutics	Aug 07, 2026	SELL	Buy +160.6% avg upside 14 analysts	$3.00 21.93% Downside	+3.3%	·
ARVN Arvinas Holding Company	Aug 07, 2026	HOLD	Buy +236.4% avg upside 28 analysts	—	-5.3%	·
SRPT Sarepta Therapeutics	Aug 06, 2026	SELL	Buy +196.2% avg upside 49 analysts	$18.00 13.59% Downside	-19.9%	·
ACAD ACADIA Pharmaceuticals	Aug 05, 2026	BUY	Strong Buy +39.7% avg upside 43 analysts	$31.00 17.39% Upside	-7.0%	·
GILD Gilead Sciences	Aug 05, 2026	BUY	Strong Buy -22.5% avg upside 66 analysts	$162.00 6.12% Upside	+15.8%	·
RYTM Rhythm Pharmaceuticals	Aug 04, 2026	BUY	Strong Buy +24.4% avg upside 22 analysts	$149.00 50.12% Upside	-7.1%	·
REGN Regeneron	Jul 30, 2026	BUY	Strong Buy -1.9% avg upside 58 analysts	$891.00 10.82% Upside	+8.2%	·
NBIX Neurocrine	Jul 30, 2026	BUY	Strong Buy +31.7% avg upside 37 analysts	$214.00 50.39% Upside	-21.2%	·
INCY Incyte	Jul 28, 2026	BUY	Buy -13.9% avg upside 48 analysts	$140.00 10.23% Upside	-3.6%	·
BCRX BioCryst	Jul 15, 2026	BUY	Strong Buy +105.7% avg upside 24 analysts	$15.00 71.06% Upside	-7.8%	·
GB:0QW0 arGEN X	Jul 02, 2026	BUY	Strong Buy -27.0% avg upside 25 analysts	—	·	·
FATE Fate Therapeutics	May 21, 2026	HOLD	Buy +370.1% avg upside 31 analysts	$2.20 14.81% Downside	+20.5%	·
NMRA Neumora Therapeutics, Inc.	Apr 01, 2025	SELL	Buy +896.7% avg upside 11 analysts	$1.00 28.45% Upside	-128.9%	·
FDMT 4D Molecular Therapeutics	Sep 19, 2024	BUY	Strong Buy +114.3% avg upside 16 analysts	$79.00 397.51% Upside	-51.1%	·
ADCT ADC Therapeutics	Oct 17, 2023	SELL	Buy +326.6% avg upside 12 analysts	$1.00 18.56% Downside	-309.9%	·
OBX Obsidian Therapeutics	Aug 11, 2023	SELL	Strong Buy +0.7% avg upside 11 analysts	$0.50 97.06% Downside	·	·
PYXS Pyxis Oncology	May 24, 2023	HOLD	Strong Buy +144.1% avg upside 15 analysts	$4.00 19.21% Upside	+14.1%	·
PRLD Prelude Therapeutics	Mar 27, 2023	SELL	Buy +124.6% avg upside 7 analysts	$6.00 23.62% Upside	+23.9%	·
PRAX Praxis Precision Medicines	Mar 06, 2023	HOLD	Strong Buy +85.5% avg upside 24 analysts	$22.50 92.59% Downside	·	·
SQZB SQZ Biotechnologies	Dec 01, 2022	SELL	Strong Buy +102677.7% avg upside 7 analysts	$20.00 83233.28% Upside	·	·
SRZN Surrozen	Nov 16, 2022	SELL	Strong Buy +100.0% avg upside 8 analysts	$1.00 94.38% Downside	+66.9%	·
TBPH Theravance Biopharma	Apr 19, 2022	SELL	Hold +8.2% avg upside 18 analysts	$9.00 47.13% Downside	-28.1%	·
KALA KALA BIO	Jul 21, 2021	BUY	Strong Buy +36090.4% avg upside 9 analysts	$8.00 1235.48% Upside	·	·
MRNA Moderna	Jan 25, 2021	HOLD	Hold -43.4% avg upside 38 analysts	$150.00 17.85% Downside	+3.8%	·
QNCX Quince Therapeutics	Jun 03, 2019	HOLD	Buy +515.1% avg upside 17 analysts	$28.00 10.69% Downside	·	·
ALEC Alector	Mar 04, 2019	BUY	Hold +394.7% avg upside 14 analysts	$26.00 1193.51% Upside	+50.2%	·
DBVT DBV Technologies SA - American	Dec 20, 2018	SELL	Strong Buy +90.7% avg upside 15 analysts	$8.00 36.59% Downside	-66.5%	·
PCRX Pacira Pharmaceuticals	Oct 10, 2018	HOLD	Buy +55.3% avg upside 22 analysts	$48.00 94.35% Upside	-19.3%	·
MCRB Seres Therapeutics	Aug 03, 2018	SELL	Buy +306.3% avg upside 11 analysts	$6.00 49.25% Upside	·	·
ACET Adicet Bio	Feb 20, 2018	BUY	Strong Buy +176.5% avg upside 14 analysts	$23.00 151.49% Upside	·	·
SPRO Spero Therapeutics	Nov 27, 2017	HOLD	Buy +910.9% avg upside 12 analysts	$16.00 1076.48% Upside	-44.6%	·
RMTI Rockwell Med	Nov 08, 2016	SELL	Buy +55.2% avg upside 11 analysts	$5.00 43.49% Downside	·	·
CORT Corcept Therapeutics	Jun 02, 2016	SELL	Buy -43.3% avg upside 16 analysts	$5.00 95.66% Downside	-92.3%	·
INVA Innoviva	Sep 09, 2015	SELL	Buy +36.8% avg upside 12 analysts	$13.00 37.97% Downside	-5.1%	·
GLNG Golar LNG	Sep 19, 2014	BUY	Strong Buy -11.3% avg upside 22 analysts	$110.00 118.09% Upside	-50.2%	·

🔒 55 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Tazeen Ahmad — Frequently Asked Questions

How accurate are Tazeen Ahmad's stock ratings?

Based on the calls 13Foresight could measure, about 48% of Tazeen's ratings were profitable over a one-year hold, with an average return of -2.0% per rating, or +17.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Tazeen ranked on 13Foresight?

Tazeen Ahmad is currently ranked #2313 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Tazeen cover?

Tazeen most recently has ratings on ARGX, RARE, PBLS, SRRK, OCUL, ASND, BNTX, KYMR, DFTX, PHVS, AMGN, BLTE and 48 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Tazeen Ahmad

Rating Distribution

Welcome to 13Foresight!